OBJECTIVES: To determine the cost-effectiveness relation of adding Saxagliptin to Metformin therapy (SAXA + MET) compared to adding Sulfonylureas (SULF + MET), in patients with type 2 diabetes mellitus (DM2) who have failed to achieve adequate glycemic control with metformin. METHODS: A discrete event simulation model (Cardiovascular Disease Registry model) with a fixed time increase based on the UKDFS-68 was used to simulate disease progression and to obtain an estimate of the treatment's economic and health consequences in DM2 patients. Clinical efficacy parameters for Saxagliptin were obtained from the literature, drug acquisition costs, adverse events (AEs) and microvascular and macrovascular complications were taken into account. The time horizon was 20 years and the perspective was that of the public health care system in Chile. Costs were expressed in US dollars (2009), with an annual 3.5% discount. RESULTS: A lower number of nonfatal events were found for the SAXA + MET-treated group versus the SULF + MET-treated group. Additionally, the model predicted a lower number of fatal macrovascular (13.2 vs. 13.6) and microvascular (19.6 vs. 19.7) events for the SAXA + MET-treated group vs. the SULF + MET-treated group. The total cost of the SAXA + MET cohort was lower than the SULF + MET cohort: US$ 15,016,011 and US$ 14,557,581, respectively. Treatments with SAXA + MET were associated in a higher number of GLYQs (9,794 vs. 9,594) and LYs (23,068 vs. 23,019) for the 100 patients’ cohort than treatment with SULF + MET; the incremental analysis per QALY and LY gained was -US$2,243 and US$ -9,182 respectively (dominant). CONCLUSIONS: Results suggest that the addition of Saxagliptin to Metformin therapy is dominant compared to the addition of Sulfonylureas; therefore, this intervention would represent an efficient use of health resources for DM2 patients in Chile.

PDB28 COST SAVINGS IN TYPE 2 DIABETES (T2D) WITH INSULIN GLARGINE COMPARED WITH INSULIN DEMETRIM IN THE UNITED KINGDOM

Tilling CJ1, Evans LM2, Keach M3

1S详情 Aventis, Guildford, Surrey, UK, 2University Hospital Llandough, Penarth, UK, 3Pharmakos, S Albans, UK

OBJECTIVES: The objective was to determine whether the use of insulin glargine (LG, Lantus) could result in cost savings in comparison with insulin detemir (ID, Levemir) in T2D patients in the UK. METHODS: Clinical data for the analysis was taken from a 1 year multi-national study (Rosenstock 2008) in 582 insulin-naïve patients treated with IG or ID as add-on therapy to oral glucose lowering drugs. IG was administered once daily in line with it’s licence and ID once (44% of patients) or twice daily (55%) according to treatment response. Mean daily insulin doses were 40U for IG and 71U for ID. Baseline characteristics were comparable on study entry. After 1 year glycaemic control, weight gain, adverse events and risk of hypoglycaemia were similar for both treatment groups. (The 2008 average annual income of urban residents was CNY 28898). The direct annual cost per patient of administering IG was CNY 591 compared with CNY 1044 for ID. Sensitivity analyses for weight gain, IG device and insulin dose confirmed the robustness of the base case results. CONCLUSIONS: IG may represent a more cost effective option for T2D patients in the UK requiring basal insulin analogue therapy with potential annual cost savings of 42% (CNY23/patient) compared with ID.

PDB29 DIRECT MEDICAL COST OF HYPOGLYCEMIA AMONG PATIENTS WITH TYPE 2 DIABETES IN THE UNITED STATES

Curkendall S1, Zhang B2, Oh K1, Williams S3, Pollack M4, Graham JP5

1Jubilant, Lexington, MA, USA, 2Vanderbilt University, Nashville, TN, USA, 3AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

OBJECTIVES: Hypoglycemia is a common treatment related side effect of diabetes, which can be associated with frequent emergency room use and hospitalization. The objective of this study was to assess the direct medical costs of individual hypoglycemia events in a US population of type 2 diabetes. METHODS: Patients >18 years with type 2 diabetes diagnosed during the period 2003 to 2008 were selected from the MarketScan® Research Databases and followed from their first diabetes diagnosis in the study period until the end of continuous coverage or December 31, 2008, whichever came first. All individual hypoglycemia events identified by a claim (ICD-9-CM 250.3, 250.8, 251.0, 251.1, 251.2) on a unique date were counted for each patient. Direct medical costs were calculated per hypoglycemia event by treatment setting and diabetes drug regimen. RESULTS: A total of 2.4 million hypoglycemia events were selected. Direct medical costs were experienced 169,248 hypoglycemia events. Costs were highest for hypoglycemia events identified in the emergency room (ER)-to-inpatient setting ($10,362/event), followed by inpatient ($7,317/event), ER ($7,070/event), and outpatient ($2,656/event) settings. Patients treated with an insulin only regimen had the highest direct medical costs of hypoglycemia ($9.49 per patient per month). Among patients treated with non-insulin regimens, the estimated hypoglycemia costs for patients on sulfonylures were $3.87 per patient per month and $0.84 for other OAIs.

PDB30 A CROSS-SECTIONAL SURVEY ON ECONOMIC BURDEN OF TYPE-2 DIABETES MELLITUS PATIENTS WITH ORAL ANTI-DIABETIC DRUGS THERAPY IN CHINA

Li X1, Ye Q2, Chang JH3, Liu GC3

1Fudan University People’s Hospital, Shanghai, China, 2Novo Nordisk (China) Pharmaceuticals Co. Ltd., Beijing, China, 3Peking University, Beijing, China

OBJECTIVES: The study assessed the economic burden incurred by type 2 diabetes mellitus (T2DM) patients with oral anti-diabetic drugs (OADs) therapy in China. METHODS: A cross-sectional survey was conducted between Dec 31st 2008 and July 31st 2009 at 75 urban hospitals in 9 cities in China. A total of 9572 T2DM patients with OADs therapy completed the self-administered questionnaires during their clinical visits. The information collected from questionnaire included demographic characteristics, utilization of OADs, glycemic control, diabetes complications, annual direct medical costs and productivity lost associated with T2DM. RESULTS: The mean age (±SD) was 59.5 ± 12.7 years, 51.1% were male and the mean diabetes duration (±SD) was 7.9 ± 6.3 years. Only 7.9% and 15.3% of the patients achieved HbA1c<6.5%, and HbA1c<7.0% respectively. The average total medical expenditure was CNY 1927.2 ± 4268.5 per patient. Annual treatment expenditure of OADs was CNY 4279.4, accounting for 66.1% of the total annual T2DM treatment expenditure. The average annual diabetes-related costs for outpatient and hospitalization were CNY 598.9 and 4369.8 respectively. T2DM patients diagnosed less than 3 years, 3-5 years, 5-10 years and more than 10 years had an average annual treatment cost of CNY 4783.0, 5829.5, 6248.4 and 8183.8 respectively. The average annual productivity loss due to T2DM was 29.9 working days. It resulted in an estimated average opportunity cost of CNY 2367.1 per capita (The 2008 average annual income of urban residents was CNY 28898). The direct treatment cost of T2DM and opportunity cost together accounted for 56% of patients’ disposable income in 2008 (CNY 15781). CONCLUSIONS: The study demonstrated the high economic burden and inadequate glucose control among T2DM patients with OADs therapy. The direct medical cost of T2DM increases with disease progression. It highlights the importance of implementing cost-effective therapeutic regimens to improve diabetes management.

PDB31 BENEFITS AND COSTS OF CONDUCTING SPONSORED CLINICAL TRIALS IN A PUBLICLY FUNDED NEW ZEALAND HOSPITAL: PRE-TRIAL, TRIAL AND FOLLOW-UP

Murphy L1, Maquire W2

1University of Tasmania, Hobart, Tasmania, Australia, 2University of Tasmania, Hobart, Tasmania, Australia

OBJECTIVES: (i) To identify and analyse the benefits and costs of sponsored clinical trials. (ii) To identify the factors that have resulted in its ability to expand clinical trials. METHODS: A systematic review of the pre-trial, trial and follow-up stages of clinical trials of the Auckland District Health Board (ADHB) was undertaken. In addition, an analysis of key financial benefits and costs of performing clinical trials was undertaken. RESULTS: We have found that the benefits of conducting clinical trials are substantial and include the improvement of treatment in the clinical area, the impact of research in the clinical area, the economic benefits during the pre-trial, trial and follow-up stages of a clinical trial. METHODS: We draw on the data relating to cases of drug treatment in two recent clinical trials to compare the economic impact of introducing new drug treatment at risk of serious cardiovascular events. The data include Ministry of Health data, The Centre for Clinical Research and Effective Practice (CReP) profit and loss statements, Counties Manukau District Health Board (CMDBH) Chronic Care Management data, trial protocols and data from a trial health outcome co-study. We identify patterns of costs and benefits during the enrolment, trial and follow-up stages of a clinical trial. RESULTS: The research unit and the health board both derive economic benefits from these trials. The magnitude of the benefits differs depending on the perspective taken. The research unit has total economic benefits ranging from US$10,465 to US$864 per participant which it is able to reinvest into other research projects. We find the benefits from the perspective of the health board are positive but small US $15 - $45 per participant over the eight year period. Savings from treatment cost avoidance are lower than anticipated. We find two periods where costs are high (1) during enrolment of patients, (2) at the end of clinical trials. CONCLUSIONS: There may be economic advantages in actively encouraging sponsored clinical trials within New Zealand publically funded hospitals. This study provides evidence of differing patterns of costs and benefits during the three stages of a clinical trial – enrolment, trial and follow-up.

PDB32 ECONOMIC EVALUATION OF RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN CANADA

Haig J1, Lawrence D2, Barbeau M3, Blouin J4, Cruess A5

1i3 Innovus, Burlington, ON, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

OBJECTIVES: Diabetic macular edema (DME) is an ophthalmologic complication that develops in a subset of patients with diabetic retinopathy and that causes loss of functionality, reduced health-related quality of life, visual impairment, and if left untreated, blindness. A cost-effectiveness analysis was conducted to measure...